Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects (307A)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00255528|
Recruitment Status : Completed
First Posted : November 21, 2005
Last Update Posted : March 20, 2007
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: metoprolol succinate||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||144 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Dose Ranging, Safety and Tolerability of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study|
|Study Start Date :||July 2002|
- To evaluate the dose range, safety, and tolerability of metoprolol CR/XL in hypertensive pediatric subjects, based on the change in sitting SBP from baseline to the end of treatment.
- Slope of placebo-corrected changes in sitting DBP: baseline to end of treatment as a function of target dose. Differences in mean change: baseline to end of treatment comparing each active group to placebo for sitting SBP and DBP.
- Safety profile
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00255528
Show 31 Study Locations
|Study Director:||AstraZeneca Toprol Medical Science Director, MD||AstraZeneca|